Novo Nordisk (NVO) May weekly option implied volatility into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BofA Securities Comments on Novo Nordisk (NVO)
May 3, 2024 5:55 AM EDTBofA Securities analyst Sachin Jain reiterated a Buy rating and $147.00 price target on Novo Nordisk (NYSE: NVO)
The analyst comments "Key takes from 1Q results: 1) 1Q24 adjusted EPS DKK5.68 +29%, 8% ahead of consensus, on 2% sales beat and operating margin 300bps ahead, mainly on S&D, offset by lower OOI (-DKK568m vs +DKK33m,... More
Novo Nordisk (NVO) sales jump on strong demand for obesity drug
May 2, 2024 6:23 AM EDTNovo Nordisk (NYSE: NVO) reported a robust first quarter with a 24% increase in sales at constant exchange rates (CER), reaching DKK 65.35 billion. The company's operating profit also saw a significant rise, jumping by 30% at CER to DKK 31.8 billion. Despite these strong results, shares of the pharmaceutical giant fell by 2.83%.
The first quarter's performance was marked by a notable 34% sales increase in North America Operations, with a 35% increase at CER. This growth was largely attributed to adjustments in gross-to-net sales from previous years. International Operations also saw an 11% rise at CER. Within the... More
